-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Benzinga·08/10/2026 16:28:54
Listen to the news
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.